Le Lézard45m
Sen-Jam Pharmaceutical Announces Planned AI Initiative for Molecule Repurposing
Sen-Jam Pharmaceutical ("Sen-Jam"), a pioneer in innovative inflammatory care, today announced a planned new initiative for use of leading-edge AI tools to accelerate the discovery and development ...
Future Market Insights21m
Anti-Microbial/Anti-Fungal Tests Industry to Hit USD 4.5 Billion by 2032 at a 5.7% of CAGR, Driven by Advances in Molecular Testing
Anti-microbial/Anti-fungal Tests Industry. The global anti-microbial/anti-fungal tests market is on a growth trajectory, with ...
Le Lézard40m
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer
Pulse Biosciences, Inc. (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationtm (nano-PFA or nsPFAtm) technology, today announced the ...
News Medical43m
Most disease-causing mutations that swap amino acids do so by making proteins less stable
Research shows 60% of missense mutations destabilize proteins, linking protein folding to genetic diseases, including ...
Precision gene editing could prevent vision loss from Stargardt disease
Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosisAfter ...
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of clinical ...